EDB Postgres ® AI Accelerates New Era of Sovereign Data and AI for Enterprises, Industries, and Nations
17.6.2025 14:00:00 EEST | Business Wire | Press release
EnterpriseDB (EDB), the leading Postgres data and AI company, today announced new innovations to the EDB Postgres AI (EDB PG AI) platform designed to help enterprises deploy and scale AI securely and compliantly across their Postgres environments, whether in clouds or on-premises. The platform streamlines operations at scale, integrates easily with existing data ecosystems, and centralizes hybrid management and observability in a single AI-ready control plane for the emerging era of agentic AI. See the demonstrations and configure your sovereign AI and platform at www.enterprisedb.com.
EDB PG AI is a unified platform with an easy-to-use interface for managing transactional, analytical, and AI workloads. As the industry’s first Postgres-based sovereign data and AI platform, it unifies relational and non-relational data in a single system, featuring automatic pipelines and built-in development tools that seamlessly automate and operationalize data for AI.
“In this AI-first, sovereign-first world, C-suite executives in every geo point to a single, urgent need: a secure, open source, sovereign data and AI platform that gives them full control over how and where they build their AI future. True data and AI sovereignty means we are giving enterprises the freedom to choose—hybrid, with unique engineered systems, software, and cloud offerings—while also ensuring that they have the security and control they need,” said Kevin Dallas, CEO, EDB.
Only 13% of enterprises globally have successfully deployed a broad set of agentic AI applications at scale, according to EDB research (May 2025). These early leaders are seeing dramatically better returns—up to 227% higher ROI than the remaining 87% and 23% better ROI than the next-best group.
“Globally, customers are increasingly turning to tested, optimized, and scalable architecture to more effectively implement open source AI at the enterprise level. To help meet this need, Red Hat collaborates through a robust partner ecosystem, including EDB, to help empower organizations with the solutions, services, and support they need to drive successful business outcomes with AI. Using EDB Postgres AI with Red Hat OpenShift AI, organizations can benefit from a more consistent platform for sovereign control of a company’s data and its own AI models,” said Stefanie Chiras, senior vice president, Partner Ecosystem Success, Red Hat.
The EDB PG AI platform introduces two new core capabilities that enable secure, scalable, and hybrid-ready agentic AI, bringing production-grade performance mainstream for enterprises across their Postgres estates:
- Low-code/no-code simplicity: AI pipeline creation in days, not months
Developers and business users can easily build intelligent applications using a simple point-and-click interface and low-code software development kit (SDK)—transforming GenAI projects from concept to production in days instead of months within a pre-integrated platform. In just five lines of code, users can set up an AI pipeline that automatically syncs embeddings with source data, ensuring an always-up-to-date AI knowledge base without costly infrastructure maintenance.
NVIDIA accelerated computing delivers the processing performance required for this new compute paradigm, while NVIDIA NIM microservices enable enterprises to run AI models locally and protect their data with sovereign AI. EDB Postgres AI integrates NVIDIA NeMo Retriever extraction, embedding and re-ranking microservices to ingest and process multimodal enterprise data, along with a catalog of NIM microservices to facilitate AI model extension.
Together, these capabilities help enterprises operationalize their AI—securely, at scale, and on their infrastructure of choice. - Sovereign hybrid Postgres data estate management and observability
Hybrid management delivers comprehensive visibility across the entire Postgres estate, empowering developers and operators with real-time insights across hundreds of databases through an intuitive interface. With 200+ built-in metrics and intelligent recommendations, teams can identify and resolve issues 5x faster, boost application performance by up to 8x, and optimize infrastructure—no DBA expertise required. Anyone can optimize performance and manage large estates with ease, boosting productivity by up to 30% while cutting TCO up to 6x compared to legacy systems.
“The EDB Postgres AI engineered solution leverages several of Supermicro’s strengths, including our portfolio of data center building block systems, experience in developing and delivering rack-scale AI solutions, and our experience in supporting OEM customers like EnterpriseDB,” said Cenly Chen, chief growth officer, senior vice president, and managing director, Supermicro B.V. “This unified solution offers full hybrid capabilities and helps customers build sovereign, scalable, and compliant data and AI systems, giving enterprises the control and near-instant access to data needed for Gen AI.”
Explore the comprehensive library of benchmarks here. Additional platform enhancements include:
- Data security at all layers with Transparent Data Encryption (TDE), supply chain security, and hardened container images from Iron Bank. Advanced security features include role-based access control with fine-grained permissions down to row level, robust audit logging for real-time threat detection, and data redaction to limit sensitive information exposure—ensuring compliance with evolving regulations including PCI DSS and SOC 2.
- Purpose-built PG AI Analytics Engine scales independently from storage and is optimized for columnar formats such as Iceberg and Delta tables, driving high performance queries across Postgres and the lakehouse ecosystem. Enterprises can unlock insights 30x faster than standard Postgres by using fresh operational data, breaking down silos, and eliminating ETL pipelines. Intelligent tiering offloads cold transactional data to storage that is up to 18x more cost efficient.
- A universal, secure data store supports all types of data models—SQL, vector, JSON, time-series, key-value, and more—for building applications with structured, semi-structured, and unstructured data types. Tiered storage and a query engine unify Postgres with scalable analytics tables in object storage. EDB PG AI delivers optimized read/write performance that scales seamlessly from high-concurrency transactions to complex analytical and vector queries, all within a hybrid, sovereign architecture. Proven performance advantages include:
- 6x better TCO and 30% faster transactional performance than SQL Server
- Up to 150x faster NoSQL performance vs. MongoDB
- Up to 4x faster NoSQL performance vs. MySQL
“McKnight Consulting Group compared the integrated EDB Postgres AI platform against a usual DIY approach using AWS. Across all the eight critical components of an enterprise AI factory, EDB Postgres AI reduced overall complexity by 67%, delivered a 3x faster design-to-delivery capability (from seven months to nine weeks), and a 38% reduction in maintenance complexity and costs,” said William McKnight, president, McKnight Consulting Group.
EDB PG AI represents a turning point for enterprises seeking to harness the full power of their data in the agentic AI era. To witness how your enterprise can accelerate AI initiatives with confidence while maintaining complete control of data assets, configure your own sovereign and AI platform at www.enterprisedb.com.
About EDB
EDB Postgres® AI (EDB PG AI) is the first open, enterprise-grade sovereign data and AI platform—secure, compliant, and scalable, on-premises and across clouds. Built on Postgres, the world’s leading database, EDB PG AI unifies transactional, analytical, and AI workloads, enabling organizations to operationalize their data and LLMs while maintaining control over sovereign environments. EDB PG AI is supported by a global partner network and delivers up to 99.999% availability as well as hybrid management and a built-in AI factory. As one of the most active contributors to the PostgreSQL project, EDB is deeply invested in the vitality of the global community. To learn more, visit www.enterprisedb.com.
EnterpriseDB and EDB are registered trademarks of EnterpriseDB Corporation. Postgres and PostgreSQL are registered trademarks of the PostgreSQL Community Association of Canada and used with their permission. All other trademarks are owned by their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618110344/en/
Contacts
Media Contact:
Will Clark
Marketbridge for EDB
Email: edb@marketbridge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom